Epigenetics and mutations in chronic myeloproliferative neoplasms

The BCR-ABL1-negative classic myeloproliferative neoplasms, polycythemia vera (PV), essential thrombocytemia (ET) and primary myelofibrosis are clonal stem cell disorders associated with an increased production of mature blood cells belonging preferentially to one cell linage.[1][1] They share

• Publication year

  2011

• Venue

  Haematologica

• Publication date

  2011-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3324/haematol.2011.052068PMID 21972209PMCID PMC3186298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms.

  2011cited by this paper
• Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

  2011cited by this paper
• New mutations and pathogenesis of myeloproliferative neoplasms.

  2011cited by this paper
• De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome

  2011cited by this paper
• JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.

  2011cited by this paper
• Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

  2011cited by this paper
• TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

  2011cited by this paper
• Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

  2010cited by this paper
• Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.

  2010cited by this paper
• Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

  2010cited by this paper
• Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin

  2010cited by this paper
• Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

  2010cited by this paper
• Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB

  2010cited by this paper
• Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.

  2010cited by this paper
• Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

  2010cited by this paper
• Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

  2009cited by this paper
• JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

  2009cited by this paper
• Advances in Understanding and Management of Myeloproliferative Neoplasms

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Additional Sex Comb-like 1 (ASXL1), in Cooperation with SRC-1, Acts as a Ligand-dependent Coactivator for Retinoic Acid Receptor*

  2006cited by this paper
• Mechanisms of leukemogenesis. I. Generation of autoreactive lymphocytes in response to a murine leukemia virus.

  1979cited by this paper

• КОМБИНИРОВАННАЯ ТЕРАПИЯ ПРИ МИЕЛОФИБРОЗЕ

  2019cites this paper
• RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia

  2019cites this paper
• Thrombocytosis

  2019cites this paper
• The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms

  2017cites this paper
• Roles of the Immune Cytokine Environment on Clonal Growth of Murine and Human Tet2 Mutant Bone Marrow Progenitors: Implications for Myelodysplastic Syndromes

  2017cites this paper
• ‘JAK–ing’ up the treatment of primary myelofibrosis: building better combination strategies

  2017cites this paper
• The Role of JAK2 in Myeloproliferative Neoplasms

  2017influential citation
• Epigenetics in Myeloproliferative Neoplasms

  2017influential citation
• ASXL1 plays an important role in erythropoiesis

  2016cites this paper
• A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells

  2016cites this paper
• Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells

  2015cites this paper
• Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.

  2015cites this paper
• Epigenetic diversity in hematopoietic neoplasms.

  2014cites this paper
• Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

  2014cites this paper
• Novel myelofibrosis treatment strategies: potential partners for combination therapies

  2014cites this paper
• Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?

  2013cites this paper
• Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

  2013cites this paper
• Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis

  2013cites this paper
• Whole Blood Transcriptional Profi ling Reveals Signifi cant Downregulation of HLA Class I and II Genes in Essential Thrombocythemia, Polycythemia Vera and Myelofi brosis

  2013cites this paper
• Myelofibrosis: an update on current pharmacotherapy and future directions

  2013cites this paper
• A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia

  2013cites this paper
• JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells

  2013cites this paper
• JAK2 Mutation-Related Disease and Thrombosis

  2013cites this paper
• Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.

  2013cites this paper
• Use of the JAK1/JAK2 inhibitor ruxolitinib in the treatment of patients with myelofibrosis

  2013cites this paper
• Novel therapies in the classical BCR–ABL-negative myeloproliferative neoplasms

  2013cites this paper
• Extramedullary hematopoiesis associated with myeloproliferative neoplasm manifesting as pleural effusion: case report and review of literature

  2012cites this paper
• Molecular Genetics in Diagnosis and Prognosis of Philadelphia Chromosome Negative Myeloproliferative Neoplasms. Molecular genetics in MPNs

  2012cites this paper
• Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.

  2012cites this paper
• BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.

  2012cites this paper
• Somatic Mutations in Polycythaemia Vera and Other Philadelphia Chromosome Negative Myeloproliferative Neoplasms

  2012cites this paper
• MOLEKULARNI MEHANIZMI PATOGENEZE MIJELOPROLIFERATIVNIH NEOPLAZIJA: POREMEĆAJ EKSPRESIJE GENA UKLJUČENIH U PROLIFERACIJU I APOPTOZU

  2012cites this paper